Axitinib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06626 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions | KG + DL |
| 2 | unclassified renal cell carcinoma | KG + DL |
| 3 | renal cell carcinoma associated with neuroblastoma | KG + DL |
| 4 | childhood kidney cell carcinoma | KG + DL |
| 5 | liposarcoma | KG + DL |
| 6 | renal carcinoma | KG + DL |
| 7 | ovarian myxoid liposarcoma | KG + DL |
| 8 | angiolipoma | KG + DL |
| 9 | collecting duct carcinoma | KG + DL |
| 10 | familial spontaneous pneumothorax | KG + DL |
| 11 | endocrine-cerebro-osteodysplasia syndrome | KG + DL |
| 12 | renal pelvis carcinoma | KG + DL |
| 13 | chromophobe renal cell carcinoma | KG + DL |
| 14 | sarcomatoid renal cell carcinoma | KG + DL |
| 15 | adenocarcinoma of liver and intrahepatic biliary tract | KG + DL |
| 16 | spindle cell liposarcoma | KG + DL |
| 17 | undifferentiated carcinoma of liver and intrahepatic biliary tract | KG + DL |
| 18 | extrahepatic bile duct adenocarcinoma | KG + DL |
| 19 | kidney medullary carcinoma | KG + DL |
| 20 | acquired cystic disease-associated renal cell carcinoma | KG + DL |
| 21 | cystic renal cell carcinoma | KG + DL |
| 22 | amyotrophic lateral sclerosis | KG + DL |
| 23 | multilocular clear cell renal cell carcinoma | KG + DL |
| 24 | paroxysmal dyskinesia | KG + DL |
| 25 | vulva sarcoma | KG + DL |
| 26 | breast fibroadenoma | KG + DL |
| 27 | renal pelvis adenocarcinoma | KG + DL |
| 28 | Mills syndrome | KG + DL |
| 29 | amyotrophic lateral sclerosis, susceptibility to | KG + DL |
| 30 | amyotrohpic lateral sclerosis type 22 | KG + DL |
| 31 | bilateral parasagittal parieto-occipital polymicrogyria | KG + DL |
| 32 | axial spondylometaphyseal dysplasia | KG + DL |
| 33 | Wolffian duct adenocarcinoma | KG + DL |
| 34 | X-linked hydrocephalus with stenosis of the aqueduct of Sylvius | KG + DL |
| 35 | glycogen storage disease due to lactate dehydrogenase H-subunit deficiency | KG + DL |
| 36 | X-linked complicated corpus callosum dysgenesis | KG + DL |
| 37 | heart fibrosarcoma | KG + DL |
| 38 | pyruvate dehydrogenase E1-beta deficiency | KG + DL |
| 39 | 3M syndrome | KG + DL |
| 40 | classic variant of chromophobe renal cell carcinoma | KG + DL |
| 41 | uterine corpus perivascular epithelioid cell tumor | KG + DL |
| 42 | kidney fibrosarcoma | KG + DL |
| 43 | fibroblastic neoplasm | KG + DL |
| 44 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | KG + DL |
| 45 | benign PEComa | KG + DL |
| 46 | autosomal dominant mitochondrial myopathy with exercise intolerance | KG + DL |
| 47 | lymphangiomyoma | KG + DL |
| 48 | familial rhabdoid tumor | KG + DL |
| 49 | monomelic amyotrophy | KG + DL |
| 50 | childhood malignant kidney neoplasm | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.